Hims & Hers Health Inc. Stock News

Investors can contact the law firm at no cost to learn more about recovering their losses

Hims and Hers faced a short-term revenue dip due to regulatory changes and GLP-1 customer offboarding, but core growth remains strong. Subscriber numbers surged 31% quarter-over-quarter, and product diversification continues to drive long-term revenue expansion. Regulatory-driven shipment cadence changes should normalize by late 2025, supporting a rebound in average revenue per customer and tot...

LOS ANGELES, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options

Hims & Hers Health (HIMS -6.11%), the telehealth company famous for selling Ozempic lookalikes over the internet, is tumbling today, down 6.7% through 10:55 a.m. ET after missing in its second-quarter earnings report last night, on both the top and bottom lines.

In this video, I will go over Hims & Hers' (HIMS -3.25%) latest earnings report and explain why the stock reacted the way it did. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment as well as the sexual health business.

Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong growth but did not meet revenue forecasts. The company disclosed revenue of $544.8 million, which reflects a strong 73% increase compared to the previous year, although it did not reach the $552 million consensus estimate.